![Martin Brenner](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Martin Brenner
Algemeen Directeur bij
IBIO, INC.
Vermogen: 58 239 $ op 31-05-2026
Profiel
Martin B. Brenner currently works at iBio, Inc., as Director, Chief Executive & Scientific Officer from 2024.
Dr. Brenner also formerly worked at AstraZeneca PLC, as Senior Director & Head-BioScience from 2012 to 2013, Merck Research Laboratories Massachusetts LLC, as Executive Director-Diabetes & NASH from 2013 to 2016, Recursion Pharmaceuticals, Inc., as Chief Scientific Officer from 2017 to 2018, Pelican, Inc., as Chief Scientific Officer & Senior Vice President from 2019 to 2020, Stoke Therapeutics, Inc., as VP & Head-Research & Early Development from 2016 to 2017, and Pfizer Inc., as Head-Insulin Resistance Group.
Dr. Brenner received his doctorate degree from Ludwig-Maximilians-Universität München and doctorate degree from The University of Veterinary Medicine Hanover.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
IBIO, INC. 0,09% | 19-03-2026 | 30.652 ( 0,09% ) | 58 239 $ | 31-05-2026 |
Actieve functies van Martin Brenner
| Bedrijven | Functie | Begin |
|---|---|---|
| IBIO, INC. | Algemeen Directeur | 20-01-2023 |
Eerdere bekende functies van Martin Brenner
| Bedrijven | Functie | Einde |
|---|---|---|
| PFENEX INC. | Hoofd Techniek/Wetenschap/O&O | 01-10-2020 |
| RECURSION PHARMACEUTICALS, INC. | Hoofd Techniek/Wetenschap/O&O | 01-01-2018 |
| STOKE THERAPEUTICS, INC. | Corporate Officer/Principal | 01-01-2017 |
Merck Research Laboratories Massachusetts LLC
 Merck Research Laboratories Massachusetts LLC Pharmaceuticals: MajorHealth Technology Discovers, develops, and markets a broad range of human and animal health products | Directeur/Bestuurslid | 01-01-2016 |
| ASTRAZENECA PLC | Corporate Officer/Principal | 01-01-2013 |
Opleiding van Martin Brenner
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
41
Eerstegraads connecties
9
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 9 |
|---|---|
Pfizer Inc.
 Pfizer Inc. Pharmaceuticals: MajorHealth Technology Engages in discovery, development, manufacturing, marketing, sale and distribution of biopharmaceutical products & ingredients | Health Technology |
AstraZeneca PLC
 AstraZeneca PLC Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products | Health Technology |
Recursion Pharmaceuticals, Inc.
 Recursion Pharmaceuticals, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biotechnology company that combines biology, chemistry, automation, data science and engineering to industrialize drug discovery | Health Technology |
Ludwig-Maximilians-Universität München
 Ludwig-Maximilians-Universität München Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Merck Research Laboratories Massachusetts LLC
Merck Research Laboratories Massachusetts LLC Pharmaceuticals: MajorHealth Technology Discovers, develops, and markets a broad range of human and animal health products | Health Technology |
iBio, Inc.
 iBio, Inc. Pharmaceuticals: OtherHealth Technology Engages in the development and commercialization of vaccines and therapeutic proteins | Health Technology |
Pelican Inc
 Pelican Inc Pharmaceuticals: MajorHealth Technology Develops biopharmaceutical therapeutics and vaccines | Health Technology |
The University of Veterinary Medicine Hanover
 The University of Veterinary Medicine Hanover Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Stoke Therapeutics, Inc.
 Stoke Therapeutics, Inc. BiotechnologyHealth Technology Operates as biotechnology company focused on the development of first-in-class therapeutics that selectively increase gene expression to treat genetic diseases | Health Technology |
Kies MarketScreener 
